95 related articles for article (PubMed ID: 9666136)
21. CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes.
Mato S; Alberdi E; Ledent C; Watanabe M; Matute C
Glia; 2009 Feb; 57(3):295-306. PubMed ID: 18814177
[TBL] [Abstract][Full Text] [Related]
22. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1.
Contassot E; Wilmotte R; Tenan M; Belkouch MC; Schnüriger V; de Tribolet N; Burkhardt K; Dietrich PY
J Neuropathol Exp Neurol; 2004 Sep; 63(9):956-63. PubMed ID: 15453094
[TBL] [Abstract][Full Text] [Related]
23. The effect of anandamide on prolactin secretion is modulated by estrogen.
Scorticati C; Mohn C; De Laurentiis A; Vissio P; Fernández Solari J; Seilicovich A; McCann SM; Rettori V
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2134-9. PubMed ID: 12578974
[TBL] [Abstract][Full Text] [Related]
24. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
Romero J; de Miguel R; García-Palomero E; Fernández-Ruiz JJ; Ramos JA
Brain Res; 1995 Oct; 694(1-2):223-32. PubMed ID: 8974649
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide.
Kaplan BL; Ouyang Y; Herring A; Yea SS; Razdan R; Kaminski NE
Toxicol Appl Pharmacol; 2005 Jun; 205(2):107-15. PubMed ID: 15893538
[TBL] [Abstract][Full Text] [Related]
26. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy.
Citraro R; Russo E; Scicchitano F; van Rijn CM; Cosco D; Avagliano C; Russo R; D'Agostino G; Petrosino S; Guida F; Gatta L; van Luijtelaar G; Maione S; Di Marzo V; Calignano A; De Sarro G
Neuropharmacology; 2013 Jun; 69():115-26. PubMed ID: 23206503
[TBL] [Abstract][Full Text] [Related]
27. Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Kokona D; Thermos K
Exp Eye Res; 2015 Jul; 136():45-58. PubMed ID: 25989217
[TBL] [Abstract][Full Text] [Related]
28. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.
Xiong W; Wu X; Li F; Cheng K; Rice KC; Lovinger DM; Zhang L
J Neurosci; 2012 Apr; 32(15):5200-8. PubMed ID: 22496565
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons.
Fisyunov A; Tsintsadze V; Min R; Burnashev N; Lozovaya N
J Neurophysiol; 2006 Sep; 96(3):1267-77. PubMed ID: 16738209
[TBL] [Abstract][Full Text] [Related]
30. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
31. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
[TBL] [Abstract][Full Text] [Related]
32. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat.
Felder CC; Nielsen A; Briley EM; Palkovits M; Priller J; Axelrod J; Nguyen DN; Richardson JM; Riggin RM; Koppel GA; Paul SM; Becker GW
FEBS Lett; 1996 Sep; 393(2-3):231-5. PubMed ID: 8814296
[TBL] [Abstract][Full Text] [Related]
33. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation.
Do Y; McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2004 Aug; 173(4):2373-82. PubMed ID: 15294950
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoid ligand-receptor signaling in the mouse uterus.
Das SK; Paria BC; Chakraborty I; Dey SK
Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
[TBL] [Abstract][Full Text] [Related]
36. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway.
Sancho R; Calzado MA; Di Marzo V; Appendino G; Muñoz E
Mol Pharmacol; 2003 Feb; 63(2):429-38. PubMed ID: 12527815
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures.
Kreutz S; Koch M; Ghadban C; Korf HW; Dehghani F
Exp Neurol; 2007 Jan; 203(1):246-57. PubMed ID: 17010339
[TBL] [Abstract][Full Text] [Related]
38. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
Gómez del Pulgar T; Velasco G; Guzmán M
Biochem J; 2000 Apr; 347(Pt 2):369-73. PubMed ID: 10749665
[TBL] [Abstract][Full Text] [Related]
39. Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB
Cruz SL; Sánchez-Miranda E; Castillo-Arellano JI; Cervantes-Villagrana RD; Ibarra-Sánchez A; González-Espinosa C
Int Immunopharmacol; 2018 Nov; 64():298-307. PubMed ID: 30243065
[TBL] [Abstract][Full Text] [Related]
40. Prediction of essential binding domains for the endocannabinoid N-arachidonoylethanolamine (AEA) in the brain cannabinoid CB1 receptor.
Shim JY
PLoS One; 2021; 16(6):e0229879. PubMed ID: 34181638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
